Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7947934 | 0.86 | CTSS (0.35) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9398219 | 0.84 | MAPT (0.37) | CTSKCTSSCA1CA2CYP1A2 | |
| SCHEMBL15014015 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15511851 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28078949 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15511852 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL16654059 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL19209613 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15014014 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1731214 | 0.81 | CYP1A2 (0.51) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060293297-A1 | Cyanofluoropyrrolidine derviative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1627870-A1 | CYANOFLUOROPYRROLIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-02-22 | — | — | EP | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293297-A1 | Cyanofluoropyrrolidine derviative | DPP4, DPP3, NPY4R | CTSK 3644/4885CTSS 3134/4885CA1 1148/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | CTSK 3152/4885CTSS 2510/4885CA1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.